Stifel lowered the firm’s price target on Baxter (BAX) to $36 from $38 and keeps a Buy rating on the shares. The firm says that overall, the Baxter Q1 quarter and the earnings call highlights seemed solid despite macro headwinds. Sales at $2.63B were better than expected vs. its estimate/consensus of $2.58B. Taken together, Stifel views the quarter’s performance positively, as it represents Baxter’s ninth-consecutive in-line or better quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter participates in a conference call with JPMorgan
- Baxter price target lowered to $33 from $36 at Wells Fargo
- Baxter International: Balancing Growth Potential and Tariff Challenges with a Hold Rating
- Baxter International Reports Strong Q1 2025 Results
- Baxter International Surpasses Q1 2025 Expectations